Treatments for hematological malignancies have improved considerably over the past decade, but the growing therapeutic arsenal has not benefited adult T-cell leukemia (ATL) patients. Oncolytic viruses such as vesicular stomatitis virus (VSV) have recently emerged as a potential treatment of solid tumors and leukemias in vitro and in vivo. In the current study, we investigated the ability of VSV to lyse primary human T-lymphotropic virus type 1 (HTLV-1)-infected T-lymphocytes from patients with ATL. Ex vivo primary ATL cells were permissive for VSV and underwent rapid oncolysis in a time-dependent manner. Importantly, VSV infection showed neither viral replication nor oncolysis in HTLV-1-infected, nonleukemic cells from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), and in naive CD4 þ T-lymphocytes from normal individuals or in ex vivo cell samples from patients with chronic lymphocytic leukemia (CLL). Interestingly, activation of primary CD4 þ T-lymphocytes with anti-CD3/CD28 monoclonal antibody, and specifically with anti-CD3, was sufficient to induce limited viral replication and oncolysis. However, at a similar level of T-cell activation, VSV replication was increased fourfold in ATL cells compared to activated CD4 þ T-lymphocytes, emphasizing the concept that VSV targets genetic defects unique to tumor cells to facilitate its replication. In conclusion, our findings provide the first essentialIntroduction Adult T-cell leukemia (ATL) is an aggressive malignancy of mature activated, CD4/CD25 þ T-lymphocytes that occurs worldwide in populations where human T-lymphotropic virus type 1 (HTLV-1) infection is endemic -southwestern Japan, the Caribbean Basin, intertropical Africa, and the southern United States. HTLV-1 has also been etiologically linked to a neurological disorder, HTLV-1-associated myelopathy/ tropical spastic paraparesis (HAM/TSP) (Uchiyama et al., 1977; Hinuma et al., 1982; Gessain et al., 1985; Osame et al., 1986) . Mechanistically, the HTLV-1 Tax oncoprotein plays a central role in the initiation of transformation by transactivating several cellular pathways (Yoshida, 2001; Franchini et al., 2003) , and by promoting the oligo/polyclonal expansion of HTLV-1-infected T cells (Mortreux et al., 2003) . Subsequently, Tax-mediated accumulation of host genome alterations leads to Tax-independent proliferation, escape from the CD8 þ T-lymphocyte anti-Tax response, and emergence of the malignant CD4/CD25 þ T-lymphocyte clone (Yasunaga and Matsuoka, 2003) .
Despite extensive progress in the understanding of the molecular virology and immunology of HTLV-I-associated diseases, there has been only minimal improvement in the treatment of ATL. Conventional as well as high-dose chemotherapy has shown only limited benefit, and the aggressive subtypes of ATL carry a very poor prognosis, with a median survival of less than 1 year (Shimoyama, 1991) . The combination of antiviral nucleosides and interferon (IFN)-a has been shown to improve the response rate and survival; however, most patients relapse and succumb to disease, thus underlining the need for new therapeutic approaches (Bazarbachi et al., 2004) .
One promising and novel cancer therapeutic approach against tumor cells is virotherapy. Several naturally occurring or genetically engineered viruses are effective in killing tumor cells in many experimental models (Steele, 2000; Wu et al., 2001; Chiocca, 2002) . Recently, vesicular stomatitis virus (VSV), an enveloped negative-strand RNA virus belonging to the Rhabdoviridae family, has been shown to possess intrinsic oncolytic properties (Balachandran and Barber, 2000; Stojdl et al., 2000) . VSV can infect a wide variety of mammalian cells and host defense to VSV infection is based on the antiviral activity of IFN before the generation of neutralizing antibody response (Grigera et al., 1996) . The ability of VSV to replicate in and lyse tumor cells occurs in part due to defects in the IFN antiviral response in tumor cells (Stojdl et al., 2000 (Stojdl et al., , 2003 Fernandez et al., 2002) . Recently, Stojdl et al. (2003) demonstrated that 80% of VSV-permissive cell lines had impaired responses to either IFN-a or IFN-b. Complete destruction of cell line-derived xenograft tumors in animal models following intratumoral injection of wild-type or genetically modified VSV have been documented (Balachandran and Barber, 2000; Stojdl et al., 2000 Stojdl et al., , 2003 Balachandran et al., 2001; Fernandez et al., 2002; Ebert et al., 2003; Huang et al., 2003; Obuchi et al., 2003) . Furthermore, systemic intravenous administration of VSV in mouse models has also shown potency in treating primary and metastasic tumors (Balachandran et al., 2001) .
The importance of IFN in the host defense against VSV was highlighted by demonstrating that mice harboring defects in IFN signaling are highly sensitive to normally sublethal exposure to VSV (Muller et al., 1994; Durbin et al., 1996) , a situation that is dramatically reversed by prophylactic IFN treatment (Stojdl et al., 2003) . Recent analysis has demonstrated that defective control of mRNA translation initiation plays a crucial role in cell permissiveness to VSV (Balachandran and Barber, 2004) , and that translation control downstream of PKR activation, frequently dysregulated in many transformed cells, can cooperate with attenuated IFN antiviral activity to facilitate VSV oncolysis.
While most studies of VSV oncolysis in vitro and/or in animal models have been performed with cell lines, preclinical data in primary cancer cells are still lacking. In this study, we investigated the oncolytic activity of VSV in primary CD4 þ T-lymphocytes from ATL patients. Ex vivo VSV infection induced significant oncolytic activity in primary ATL cell in a time-and dose-dependent manner. These studies provide the first essential information for the development of a VSVbased treatment for ATL.
Materials and methods
Cells and reagents HTLV-1 T-cell lines MT-2 and MT-4 cells were purchased from American Type Culture Collection (ATCC) and maintained in RPMI 1640 medium supplemented with 10% FCS (Wisent) and 100 U/ml penicillin/streptomycin (referred to as complete RPMI 1640). The human Epstein-Barr virustransformed B-cell chronic lymphocytic leukemia (B-CLL) I-83 cell line and Epstein-Barr virus-negative B-CLL WSU cell line were cultured in complete RPMI 1640. Peripheral blood mononuclear cells (PBMCs) from four ATL patients (samples ATL-1, ATL-2, ATL-3, and ATL-4), two patients with HAM/ TSP (HAM-1 and HAM-2), three patients with B-CLL (CLL-1, CLL-2, and CLL-3), one patient with T-CLL (CLL-4), and three healthy individuals were obtained after informed consent. PBMCs were isolated by centrifugation (400 g at 201C for 25 min) of blood on a Ficoll-Hypaque gradient (Amersham Pharmacia Biotech). PBMCs were resuspended in RPMI 1640 medium supplemented with 15% heat-inactivated FBS, 100 U/ml penicillin-streptomycin, and 70 U/ml of humanrecombinant IL-2 (rIL-2, Roche Diagnostics, Mannheim, Germany).
Isolation of T cells
Freshly isolated PBMCs were incubated with CD4 enrichment cocktail (Miltenyi Biotec) and CD4 þ T-lymphocytes were negatively selected with the high-speed autoMACS system (Miltenyi Biotec) according to the manufacturer's instructions. In all cases, the purity of CD4 þ T-lymphocytes was between 90 and 95% as determined by flow cytometry. Isolated CD4 þ T cells were cultured in complete RPMI 1640.
T-cell activation
Purified CD4 þ T-lymphocytes (10 6 /ml) were mock activated or activated in vitro for 24 h with 5 mg/ml of immobilized anti-CD3 monoclonal antibody, and 1 mg/ml of immobilized anti-CD28 monoclonal antibody (BD Biosciences), in the presence of 70 U/ml of rIL-2. Cells were then harvested, washed, and cultured in complete RPMI 1640.
Virus production, quantification, and infection Wild-type VSV (Indiana serotype) and rVSV-GFP were propagated in BHK-21 cells as described previously (Stojdl et al., 2003) . Viruses were obtained from cell-free supernatants and titrated on Vero cells by standard plaque assay. Cells were mock infected or infected with VSV at an MOI of 1 PFU/cell for 1 h in RPMI 1640 at 371C. In some experiments, caspase-3 inhibitors zVAD-FMK or D-VAD-FMK were added to a final concentration of 100 mM at 20 min prior to VSV infection. The cells were then washed with PBS and incubated with complete RPMI 1640 at 371C for the indicated times. Following incubation, cells were harvested in PBS, pelleted, and processed for protein analysis. For indicated experiments, cells were mock infected or infected with rVSV-GFP under similar conditions and GFP expression was analysed by FACScaliburt flow cytometry.
Immunoblot analysis
Cells destined for immunoblotting were washed with PBS and lysed in lysis buffer (0.05% NP40, 1% glycerol, 30 mM NaF, 40 mM b-glycerophosphate, 10 mM Na 3 VO 4 , 10 ng/ml of protease inhibitors (leopeptine, aprotinine, and pepstatine)). Protein concentration was determined with Bio-Rad protein assay reagent (BioRad), and 20 mg of protein was then resolved using 12% SDS-PAGE and transferred to nitrocellulose membrane (Hybond C Super; Amersham, Oakville, Canada). Blots were blocked for 1 h at 251C in 5% nonfat dried milk in PBST (PBS þ 0.5% Tween-20). Membranes were then incubated overnight with rabbit anti-VSV, anti-Rho GDPdissociation inhibitor (Rho-GDI) (BD Pharmingen, 1:5000), anti-procaspase-3 (Upstate, 1:1000), anti-cleaved caspase-3 (Cell Signaling, 1:2000), anti-DNA fragmentation factor-45 (DFF-45) (Sharif-Askari et al., 2001) (1:3500), or mouse antib-actin (Chemichon, 1:10 000) at 251C. The blots were then washed three times in PBST and reincubated in the presence of horseradish peroxidase-conjugated goat anti-rabbit or antimouse antibodies (Amersham, 1:3000) for 1 h at 251C. 
Measurement of apoptosis
Apoptotic cells were analysed by annexin V/7-amino-actinomycin D (7-AAD) double staining for detection of the apoptotic plasma membrane (phosphatidylserine translocation). Mock-or VSV-infected cells were washed and resuspended in 300 ml of ice-cold annexin V binding buffer (HEPESNaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 (BD Pharmingen)), incubated on ice for 15 min with 1 ml of each of fluorescein isothiocyanate (FITC)-conjugated annexin V and 7-AAD (BD Pharmingen), and followed by flow cytometric analysis. For DNA content staining, cells were collected, washed in ice-cold PBS/5 mm EDTA, and fixed in ethanol (70% in PBS) overnight at À201C. After fixation, cells were then washed in PBS, and stained with a PI staining solution (PBS, 50 mg/ml PI, 100 U/ml RNase A and 1 mg/ml glucose) for 2 h at room temperature before FACS s analysis. For each sample, the forward versus right-angle scatter cytogram was used to exclude debris and aggregates. Apoptosis was determined by quantification of the sub-G 0 population (1 Â 10 4 cells/measurement).
Results

VSV replicates and induces rapid cell death in HTLV-1-transformed cells
Wild-type VSV has been shown to induce potent cytolytic effects against a wide range of tumor cells, including 80% of the NCI human tumor cell line panel (Weinstein et al., 1997) . Thus, we first sought to determine the ability of VSV to replicate and induce cell death in the HTLV-1-infected T-cell lines, MT-2 and MT-4. VSV infection was accompanied by cell death; quantification by acridine orange-ethidium bromide fluorescent-dye staining showed that cell death was time dependent (Figure 1a ), and by 48 h post-VSV infection, no significant viable cells were detected. Cell death was correlated with VSV replication; as shown in Figure Oncolytic activity of VSV in ATL R Césaire et al cleavage was assessed in MT-4 cells (Woo et al., 1998; . As shown in Figure 2a , immunoblot analysis using anti-VSV antiserum revealed significant VSV replication, with VSV G and N protein expression observed as early as 2 h postinfection ( Figure 2a , lane 4). Concomitant with viral replication, VSV infection for 4 h was sufficient to cleave procaspase-3 to its enzymatically active p20 and p17 subunits (Figure 2a , lane 5). The enzymatic activity of caspase-3 in VSV-infected cells was further monitored by immunoblot analysis of two caspase-3 substrates, the Rho-GDI, and the DFF45 (Na et al., 1996; . Both substrates were processed in a time-dependent manner beginning at 4 h postinfection (Figure 2a , lanes 5-9). Furthermore, the use of two broad-spectrum caspase-3 inhibitors -zVAD and DEVD -significantly delayed the onset of VSV-induced caspase-3 activation and Rho-GDI processing in MT-4 cells ( Figure 2b) ; the 19 and 17 kDa forms of cleaved caspase-3 were weakly detectable at 10 h postinfection in the presence of DEVD (Figure 2b , lanes 8 and 9), while in the presence of zVAD, cleaved caspase-3 was barely detected at 6-12 h (Figure 2b, lanes 13-16) . In the presence of both inhibitors, the majority of the 32 kDa procaspase-3 remained uncleaved (Figure 2b ). Rho-GDI cleavage in the presence of both inhibitors was also significantly delayed ( Figure 2b , lanes 5-8 and 13-16). There was in contrast only a slight delay in the kinetics of VSV replication in the presence of DEVD or zVAD, with VSV G and N protein expression observed at 4 h postinfection ( Figure 2b , lanes 4, 11, and 12). Collectively, these data demonstrate that HTLV-1-transformed T cells are permissive for VSV replication, which in turn induces rapid caspase-dependent oncolysis of infected cells.
VSV replicates and induces rapid cell death in primary ATL cells
To investigate the ex vivo responses of primary ATL cells to VSV infection, PBMCs were obtained from four patients with acute ATL disease; samples were collected at the time of diagnosis before chemotherapy. The survival time of ATL-1, -2, -3, and -4 patients were 40 days, 30 days, >9 months, and 14 months, respectively. Hematological analysis revealed that PBMCs from ATL-1, -2, -3, and -4 patients contained substantial leukemic cells: 79, 39, 77, and 40% atypical lymphocytes, respectively (Table 1) . Following Ficoll purification and culture, the percentage of CD4 þ CD8À CD25 þ T leukemic cells ranged between 76 and 89%. In parallel, PBMCs were collected from two patients with HAM/TSP, and a healthy volunteer (naive PBMC) ( Table 1) . Cells (ATL, HAM/TSP, and normal PBMC) were mock infected or infected with the rVSV-GFP (MOI of 1.0 PFU/cell) for various times and the level of GFP expression (as a measure of virus replication) was examined by flow cytometry. GFP-expressing cells (10-15%) were detected in all ATL samples beginning at 24 h and the percentage of GFP-positive cells increased in a time-dependent manner (30-40% at 72 h) (Figure 3a , and data not shown). On the other hand, no increase in GFP expression was detected in HAM/TSP or naive PBMC even after 72 h of VSV infection (Figure 3a) , illustrating the permissiveness of VSV in ATL cells. VSV induced dramatic cell death (>50% at 24 h and >70% at 72 h) only in ATL cells but not in HAM/TSP or naive PBMC (Figure 3b ). In parallel, immunoblot analysis from ATL-infected cells clearly revealed time-dependent processing of procaspase-3 and Rho-GDI at 24 h postinfection, concomitant with viral replication (Figure 3c ). High levels of apoptotic ATL cells at 24 and 72 h again indicates that cell death may be occurring through both direct virusmediated and indirect apoptotic mechanisms. (Figure 4a ). As shown in Figure 4b , both I-83 and WSU were GFP positive (>70 and 40%, respectively) at 24 h after rVSV-GFP infection. The time-dependent induction of cell death was confirmed by annexin V and 7-AAD staining in infected but not control cells, and revealed extensive cell death (60 and 76%, respectively) as early as 16 h postinfection (Figure 4c) . VSV replication was then assessed in primary cells from three B-CLL and one T-CLL patients, with the samples containing more than 60% leukemic cells. In contrast to I-83 and WSU cell lines, primary CLL cells infected ex vivo under similar conditions were not permissive to VSV replication ( Figure 4d ). Furthermore, VSV infection of primary CLL cells showed no increase in cell death as measured by annexin V staining (Table 1) , although these CLL samples were efficiently killed by chlorambucil, etoposide or campthotecin (data not shown). Similar results were observed for primary CLL cells at an MOI as high as 100 PFU/cell. These data emphasize the ex vivo specificity of VSV oncolytic activity in primary ATL but not primary CLL cells.
Activation of CD4 T-lymphocytes renders them susceptible to VSV replication and cell death
Previous studies have demonstrated that activation of the IL-2/IL-2R loop during the acute phase of HTLV-1 infection contributes to the activation and proliferation of HTLV-1-infected CD4 þ CD25 þ subset of ATL cells (Maruyama et al., 1987; Satoh et al., 2002) . Thus, we next examined the effect of cell activation on VSV permissiveness and cytolytic activity. CD4 þ T-lymphocytes were mock activated or activated with anti-CD3/ CD28 (5 mg/ml) and IL-2 (70 U/ml) for 24 h, followed by infection with VSV (MOI of 1.0 PFU/cell) for different time intervals. The activation status of CD4 þ T cells was first analysed by flow cytometry against CD25 and CD69 activation markers at the time of VSV infection ( Figure 5a ). VSV infection of anti-CD3/CD28-activated primary CD4 þ T cells resulted in VSV replication ( Figure 5c , right panel) compared to nonstimulated cells ( Figure 5c , left panel), indicating a relationship between T-cell activation status and VSV replication. Furthermore, VSV replication in anti-CD3/CD28-activated, CD4 þ lymphocytes resulted in significant cell death by 48 h postinfection with more than 50% of the cells in the sub-G fraction, whereas in unstimulated primary CD4 þ T cells, the sub-G fraction was only 7%. Treatment with anti-CD3/CD28 or VSV alone modestly increased the sub-G proportion to 15% (Figure 5b ). In another experiment, PMA treatment of CD4 þ T cells induced significantly higher levels of cell activation compared to anti-CD3/CD28 stimulation (CD69 positivity B99 versus B33%, respectively) and was accompanied by extensive VSV replication and cell death (data not shown).
ATL cells are more permissive to VSV replication than activated CD4 T-lymphocytes Next, the replicative capacity of VSV was examined in ATL cells versus CD4 T-lymphocytes activated to similar levels. For this purpose, anti-CD3/CD28 was used to optimize the intensity of T-cell activation, using an ATL sample that was 86% CD4 þ , and a primary Tlymphocyte sample that was 96% CD4 þ . Activation of CD4 þ T cells with anti-CD3/CD28 increased the CD25 expression level (B32% with 2.5 mg/ml of anti-CD3 and B38% with 5 mg/ml of anti-CD3) comparable to the CD25 level detected for ATL cells, 46% (Figure 6a ). Following VSV infection for 24 and 48 h, immunoblot At 48 h postinfection, mock-and VSV-infected cells were analysed for annexin V staining by flow cytometry. The VSV-induced cell death was estimated by the difference between the percentages of annexin V-positive cells in the VSV-and mock-infected samples. Data from CLL, HAM/ TSP and healthy controls are indicated.
Oncolytic activity of VSV in ATL R Césaire et al analysis demonstrated that VSV replication in activated CD4 þ T-lymphocytes was time dependent and directly related to the intensity of cell activation (Figure 6b ). Nevertheless, ATL cells showed fourfold higher levels of viral G and N proteins at 24 h after infection compared to activated CD4 þ T cells under similar conditions, indicating that ATL leukemic cells were more permissive to VSV than activated, primary T-lymphocytes.
To further evaluate T-cell activation and VSV permissiveness, anti-CD3 and anti-CD28 were used separately to stimulate the CD4 þ T-cell population (Figure 6c) . Clearly, CD3 stimulation of the CD3 pathway was sufficient to render T cells permissive to VSV replication (Figure 6c, lanes 3 and 4) , whereas stimulation of the CD28 pathway had little effect on the capacity of the T-cell population to support VSV replication (Figure 6c, lanes 5-7) . As expected, the combination of CD3/CD28 rendered CD4 þ T cells permissiveness for VSV replication, but with minimal additive effect compared to CD3 stimulation alone (Figure 6c, compare lanes 3 and 4 with lanes 9 and 10) . In related experiments, no change in the expression of translational components eIF2a, B or Be (data not shown) was observed, as described previously (Balachandran and Barber, 2004) . Thus, a critical component of the ability of VSV to replicate in CD4 þ Tlymphocytes is the stimulation of the TCR/CD3 activation pathway.
Discussion
Oncolytic viruses provide an attractive potential cancer therapeutic because of their ability to replicate selectively within tumor but not normal cells. Several oncolytic viruses have demonstrated promising results in preclinical and early clinical studies Chiocca, 2002; Hawkins et al., 2002; Lichty et al., 2004) , including naturally attenuated replication competent viruses such as reovirus (nonenveloped, double-stranded (ds)RNA), parvoviruses (nonenveloped, single-stranded DNA), Newcastle disease virus, measles virus, and VSV (Gromeier and Wimmer, 2001; Kirn et al., 2001; Norman et al., 2001; Bell et al., 2002; Hawkins et al., 2002) . The present study provides the first conclusive evidence that VSV can replicate selectively in and cause extensive caspase-dependent oncolysis of primary ex vivo ATL cells. Importantly, VSV infection did not induce cell death in naive primary CD4 þ T-lymphocytes from healthy volunteers or in PBMCs from patients with HAM/TSP. VSV specifically replicates in tumor cells due to the attenuation of the antiviral IFN response, a phenotype Oncolytic activity of VSV in ATL R Césaire et al that frequently arises during tumor evolution (Linge et al., 1995; Sun et al., 1998; Matin et al., 2001) . The induction of type I IFN-a/b is a potent host defense mechanism against viral infection, and many viruses have evolved strategies to overcome the antiviral effects of this cytokine. However, VSV is extremely sensitive to the antiviral actions of IFN (Belkowski and Sen, 1987) ; hence, VSV infection in humans is asymptomatic in most cases or results in a mild febrile illness. In contrast, mice harboring a defective IFN system are highly sensitive to normally harmless exposure of VSV (Muller et al., 1994; Durbin et al., 1996) . Stojdl et al. (2003) demonstrated recently that 80% of the NCI 60 cell line collection (Weinstein et al., 1997) is permissive for VSV infection. Indeed, most of these cells were found to have impaired responses to either IFN-a or IFN-b (Stojdl et al., 2003) . In the context of the present study, we observed that IFN production in ATL cells is defective compared to primary T cells (S Oliere et al., unpublished) and experiments are underway to examine the relationship between IFN induction and VSV replication. Subsequent biochemical analysis provided evidence that translation control downstream of PKR activation, frequently dysregulated in many transformed cells, can cooperate with the attenuated IFN antiviral activity to facilitate VSV oncolysis (Balachandran and Barber, 2004) . Elevated levels of eIF2Be are required for increased permissiveness of transformed cells to VSV replication. Cells transfected with siRNA against eIF2B were almost completely protected against VSV-induced cytolysis and produced 10-fold lower yield of virus than control cells (Balachandran and Barber, 2004) . In the present study, no evidence of changes in the expression of eIF2B was obtained in resting or activated CD4 þ T-lymphocytes, suggesting that alternative mechanisms may be operative in the T-cell context. In this regard, triggering the TCR/CD3 activation pathway was sufficient to render normal CD4 þ T-lymphocytes permissive for VSV replication. This preliminary observation suggests that dissection of the CD3 pathway may identify critical downstream regulators of VSV replication and/or susceptibility to oncolysis. Since activation of Ras/Raf signaling is downstream of CD3 activation, the possibility exists that activated Ras may be required for VSV oncolysis, as previously demonstrated for Reovirus-induced oncolysis (reviewed in Norman et al., 2001) .
Interestingly, nonleukemic cells from patients with HAM/TSP were resistant to VSV infection. Since HAM/TSP cells are known to spontaneously proliferate in vitro (Cavrois et al., 1996; Mortreux et al., 2003) , an important caveat to consider in the interpretation of the present results is that the HTLV-1-infected subpopulation (1-5%) within the HAM/TSP PBMC samples may in fact be susceptible to VSV oncolysis. It is well documented that HTLV-1 infection, and specifically the viral Tax oncoprotein, leads to T-cell activation via an IL-2/IL-2 receptor autocrine loop, as well as induction of the NF-kB and CREB pathways (Yoshida, 2001; Franchini et al., 2003) ; activation of these Tax-mediated pathways may also influence the susceptibility of the HTLV-1-infected subpopulation in HAM/TSP to VSV infection. It will be of interest to determine the differential sensitivities of the HTLV-1-infected and -uninfected compartments in HAM/TSP.
Programmed cell death represents the convergence of multiple apoptotic pathways from numerous distinct initiating events and insults (Eastman and Rigas, 1999; Nguyen and Wells, 2003) . While many of the details of direct and indirect mechanisms of VSV-induced apoptosis remain to be determined, the role of viral replication in VSV oncolysis is also controversial. It Oncolytic activity of VSV in ATL R Césaire et al has been reported that VSV-induced cell death occurs at early stages after infection, and requires viral particle internalization and uncoating, but not viral replication or de novo viral protein synthesis (Gadaleta et al., 2002) .
In contrast, other studies demonstrated that VSVinduced apoptosis correlates with viral protein expression, and that activation of caspase-3-like proteases was required for VSV-induced apoptosis but not viral replication (Hobbs et al., 2001 (Hobbs et al., , 2003 . In addition, VSV matrix M protein has been shown to inhibit host cell gene expression and nuclear export of host mRNA via an association between M protein and Nup98, a host nuclear pore protein, with subsequent induction of apoptosis (Kopecky et al., 2001; Desforges et al., 2002; Kopecky and Lyles, 2003) . The present results in HTLV-1-transformed MT-4 cells and in primary ATL demonstrate that VSV-induced apoptosis correlated with VSV replication, and that caspase-3 activation and subsequent apoptotic events involving Rho-GDI cleavage and DFF45 processing occurred only following VSV replication. Nonetheless, both direct virusmediated apoptotic mechanisms and indirect mechanisms involving proapoptotic cytokine release may be involved in ATL killing by VSV. Based on the discrepancies between VSV killing of established hematopoietic cells and primary leukemic cells documented in the present study, the oncolytic activity of VSV in immortalized cell lines may not systematically reflect VSV killing in their primary cancer counterparts, thus underscoring the need to assess the sensitivity of primary cancer cells to virotherapy. While CLL cell lines were permissive for viral replication, primary CLL cells were resistant to VSV replication and subsequent cell death. This discrepancy in VSV oncolysis may be due to the fact that CLL cells do not proliferate but remain in G 0 ex vivo (Meinhardt et al., 1999; Caligaris-Cappio, 2003) . That VSV oncolysis may be linked to the state of cell growth or activation was addressed in primary T cells by demonstrating that TCR/CD3 activation enhanced permissiveness to VSV replication. It should be noted, however, that even in activated T cells, viral replication was about fourfold higher in ATL cells than in activated CD4 cells, further supporting the idea that VSV replication may be influenced by genetic defects unique to tumor cells, including deficiencies in antiviral IFN-a/b and p53 signaling pathways (Stojdl et al., 2000 (Stojdl et al., , 2003 Takaoka et al., 2003) . Thus, p53 dysfunction, myc overexpression, or p16
INK4a inactivation in ATL cells (Yoshida, 2001; Matsuoka, 2003) could increase the susceptibility of ATL cells to VSV and other oncolytic viruses (Balachandran et al., 2001; Chiocca, 2002) .
Although we provide information on the ex vivo oncolytic potential of VSV in primary ATL cells, we cannot predict the oncolytic efficiency of VSV in vivo before the onset of potentially neutralizing antibody response. Interestingly, naturally occurring VSV variants with a mutated matrix protein unable to block the IFN production in infected cells have been shown to retain oncolytic activity in a variety of in vivo models (Stojdl et al., 2003) . The possibility to enhance the oncolytic activity of VSV using genetic engineering to insert immunomodulatory or suicide cassettes has also been demonstrated both in vitro and in vivo models (Fernandez et al., 2002) . These findings further highlight the potential of VSV in cancer virotherapy and emphasize the importance of future investigations in primary ex vivo tumor cells. Kinetics of VSV replication in CD4 and ATL lymphocytes. Activated CD4 lymphocytes and ATL cells were mock infected or infected (VSV-HR, MOI of 1 PFU/cell), and at the indicated times postinfection, total cell lysates were prepared and VSV G and N protein expression was analysed in 20 mg of total cell lysates by SDS-PAGE and immunoblot analysis. (c) CD3 activation of CD4 þ T-lymphocytes. Purified isolated CD4 þ T-lymphocytes were incubated with 5.0 mg/ml of anti-CD3 monoclonal antibody or anti-CD28 monoclonal antibody for 24 h and then infected with VSV at an MOI of 1 PFU/cell. At the indicated times postinfection, total cell lysates were prepared and VSV G and N protein expression was analysed in 20 mg of total cell lysates by SDS-PAGE and immunoblot analysis with b-actin as a loading control.
